ClinicalTrials.gg
CompletedNCT04952467Updated Jan 14, 2022

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

A Phase 1 interventional study of 14C-XEN1101 in Healthy Volunteers, sponsored by Xenon Pharmaceuticals Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-14.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-XEN1101 in healthy adult male subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • XEN1101
  • Mass Balance
  • Phase 1
03

In context

Lead sponsor

Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kg/m2
  • Must be willing and able to communicate and participate in the whole study
  • Provide written
  • Adhere to the specified requirements

Key Exclusion Criteria:

  • Subjects who have received any medicinal product (IMP) in a clinical research study within 90 days
  • Evidence of any current infection or an infection within 14 days before study drug administration
  • History of any drug or alcohol abuse in the past 2 years
  • Subjects with pregnant or lactating partners
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
  • Participation in a clinical trial involving administration of radiolabelled compound(s) within 180 days of the planned dosing date of this study
  • abnormal clinical chemistry, haematology, coagulation or urinalysis. Subjects with Gilbert's Syndrome will be excluded.
  • Confirmed positive drugs of abuse test result
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) antibody results
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Drug: (14C)-XEN1101

    Subjects will receive oral 14C-XEN1101 under fed conditions.

    Drug: 14C-XEN1101

Interventions

  • Drug14C-XEN1101

    Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101

06

What researchers measure

Primary outcomes

  1. Total radioactivity excreted in urine and faeces following oral administration of XEN1101

    Cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and expressed as a % of the radioactive dose administered (Cum%Ae(total)) following oral administration of 14C-XEN1101

    Time frame: From Screening up to Day 57 post-dose

Secondary outcomes

  1. 14C Metabolite profiling in of plasma, urine and feces

    Chemical structure of each metabolite classified as \>10% (by AUC) of total radioactivity in plasma and \>10% dose excreted in urine and faeces following oral administration of XEN1101

    Time frame: From Screening up to Day 57 post-dose

  2. Pharmacokinetic (PK) data for 14C-XEN1101; Tmax

    Time of maximum observed concentration for XEN1101 and metabolites in plasma and for total radioactivity in plasma and whole blood following oral administration of 14C-XEN1101

    Time frame: From Screening up to Day 57 post-dose

  3. PK data for 14C-XEN1101; Cmax

    Maximum observed concentration for XEN1101 and metabolites in plasma and for total radioactivity in plasma and whole blood following oral administration of 14C-XEN1101

    Time frame: From Screening up to Day 57 post-dose

  4. PK data for 14C-XEN1101; T1/2

    Terminal elimination half-life for XEN1101 and metabolites in plasma and for total radioactivity in plasma and whole blood following oral administration of 14C-XEN1101

    Time frame: From Screening up to Day 57 post-dose

  5. Mass balance data for 14C-XEN1101 in urine

    CumAe(urine)expressed as a percentage of the radioactive dose administered (Cum%Ae(urine))

    Time frame: From Screening up to Day 57 post-dose

  6. Mass balance data for 14C-XEN1101 in feces

    CumAe(feces) expressed as a percentage of the radioactive dose administered Cum%Ae(feces)

    Time frame: From Screening up to Day 57 post-dose

  7. Plasma whole blood concentration ratios for total radioactivity

    Evaluation of whole blood:plasma concentration ratios for total radioactivity for corresponding time points

    Time frame: From Screening up to Day 57 post-dose

  8. Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations

    Time frame: From Screening up to Day 57 post-dose

07

Study locations

1 site
  • Quotient Sciences
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Oct 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2021
First posted
Jul 7, 2021
StartActual
Jul 14, 2021
Primary completionActual
Oct 4, 2021
CompletionActual
Oct 4, 2021
Last update
Jan 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04952467
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Jul 14, 2021
Primary completion
Oct 4, 2021
Completion
Oct 4, 2021
Last update
Jan 14, 2022

Study contacts

Study Director
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion